Rendelés típusa:
Online bejelentkezés az myHealzz rendszerével történik, ami regisztrációhoz kötött!
2021.év
1. Holló G, Katsanos A, Boboridis GK, Irkec M, Konstas AGP. Letter to the Editor: Topical preservative-free ophthalmic treatments an unmet clinical need. Exp Opin Drug Delivery 2021, Article ID: IEDD 1898866, doi: 10.1080/17425247.2021.1898866.
2. Holló G: Letter-to the Editor: Optical coherence tomography angiography and visual field progression in primary angle closure glaucoma. J Glaucoma 2021; 30: e375.
3. Holló G. Comparison of inner macular thickness and superficial macular capillary vessel density acquired using classic and high definition optical coherence tomography angiography scans. Modeling and Artificial Intelligence in Ophthalmology MAIO [Internet]. 2021 Sep. 17 [cited 2021 Sep. 18];3(1):43-54. Available from: https://www.maio-journal.com/index.php/MAIO/article/view/112
4. Konstas, APG, Holló G, Katsanos A, Boboridis KG, Haidich A-B, Dutton GN. Is it really the same? Correspondence. Br J Ophth 2021, https://bjo.bmj.com/content/104/11/1512.response, s published online on12 April 2021
5. Katsanos A, Riva I, Bozkurt B, Holló G, Quaranta L, Oddone F, Irkec M, Dutton GN, Konstas AGP. A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension. Exp. Opin. Drug Saf. 2021; doi.org/10.1080/14740338.2022.1996560, Published online: 29 Oct 2021.
6. Holló G. Exfoliation (pseudoexfoliation) syndrome (with or without glaucoma) is associated with clinically significant nonvascular systemic diseases. European Glaucoma Society, Tip of the Month November 2021. https://www.eugs.org/data1/tip_of_the_month/000151.pdf
2022.év
7. Oddone F, Kirwan J, Lopez-Lopez F, Zimina M, Fassari C, Holló G. Switching to preservative-free tafluprost/timolol fixed-dose combination in the treatment of open-angle glaucoma or ocular hypertension: subanalysis of data from the VISIONARY Study according to baseline monotherapy treatment. Adv Ther 2022;39:3501 - 3521., https://doi.org/10.1007/s12325-022-02166-6
8. Holló G, Kirwan J, Lopez-Lopez F, Zimina M, Fassari C, Oddone F, the VISIONARY study group. A comparison of country-level data from the VISIONARY study examining treatment outcomes with preservative-free tafluprost/timolol fixed-dose combination therapy. Curr Med Res 2022;38(7): 1189–1201, doi: 10.1080/03007995.2022.2083324 .
9. Holló G. Letter-to-the-Editor: The association between regional macula vessel density and central visual field damage in advanced glaucoma eyes. J Glaucoma 2022;10:e105, doi: 10.1097/IJG.0000000000002086.
10. Holló G. Corneal hysteresis as a risk factors for progresion. International Glaucoma Review 222-4, 2022; 4: 36-37. ISSN 1566-1040.
2023.év
11. Holló G. Fontos beszélgetések szembetgségekről szembetegeknek, kockázati csoportba tartozóknak és ép látásúaknak. e-könyv, 2023, Szemészeti Központ, Prima Medica Egészségközpontok, Budapest ISBN: 978-615-01-7207-1
12. Kita Y, Holló G, Mochizuki T, Emoto Y, Kita R, Hirakata A. Effect of topical pilocarpine instilled before laser peripheral iridotomy on regional iris thickness in primary angle closure disease: a swept-surce anterior segment optical coherence tomography pilot study. Seminars in Ophthalmology 2023, published online on 30 January, doi: 10.1080/08820538.2023.2169580
13. Emoto Y, Hollό G, Kita Y, Saito T, Kita R. Influence of refractive error on circumpapillary structure–function vs. vessel density–function relationships in open-angle glaucoma. J Glaucoma published online firs 14 June 2023 doi: 10.1097/IJG.0000000000002251
14. Stalmans I, Lim KS, Oddone F, Fichtl M, Belda JI, Hommer A, Laganovska G, Schweitzer C, Voykov B, Zarnowski T, Holló G. MERCURY 3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension.Graefe's Arch. Clin. Exp. Ophth 2023, accepted for publication on 23 July 2023.
1. Oddone F, Saborio G, Pavacic-Astalos J, Scorcia V, Valladares M, Holló G. Treatment of open angle glaucoma (OAG)or ocular hypertension (OHT) with preservative-free tafluprost/timolol fixed dose combination in a real world setting: analysis by diagnostic sub-group at study entry. 9th World Glaucoma Congress 2021, online congress, narrated poster, july 30 - June 3 2021.
2. Lopez-Lopez F, Fassari C, Iester M, Oddone F, Holló G. Treatment of open angle glaucoma (OAG) or ocular hypertension (OHT) with tafluprost/timolol fixed dose combination in a real world clinical practice setting: a cross country subanalysis. 9th World Glaucoma Congress 2021, online congress, narrated poster, july 30 - June 3 2021.
3. Holló G. Treatment of ocular hypertension and open-angle glaucoma with preservative-free Tafluprost/Timolol fixed-dose combination therapy. XI. Congress of the Czech Glaucoma Society, 9-10 April 2021, online participation.
4. Holló G. Exfoliation Glaucoma: How to diagnose and treat? 9th World Glaucoma Congress 2021 (online congress), 30 June-03 July 2021.
5. Holló G. OCT angiography for glaucoma progression. Congress of the Slovenian Glaucoma Society (online) 20-22 May 2021.
6. Holló G. Pathophysiology of exfoliation syndrome and exfoliative glaucoma. 10th Korean English Glaucoma Academy (online participation) 29-30 May 2021.
7. Holló G. OCT angiography for glaucoma detection and detection of glaucomatous progression. 10th Korean English Glaucoma Academy (online participation) 29-30 May 2021.
8. Holló G. Pathophysiology of pseudoexfoliation syndrome and pseudoexfoliative glaucoma. Invited review lecture. 5th Asia-Pacific Glaucoma Congress 4-8 June 2021 (online lecture 354, 06 June 2021).
9. Holló G, Kóthy P. Konzerválószer-mentes tafluprost/timolol fix kombinációra váltás prosztaglandin analógról vagy timololról: a VISIONARY Vizsgálat. Magyar Szemorvostársaság kongresszusa 2021 (online). 2021. június 5.
10. Oddone F, Saborio G, Pavacic-Astalos J, Scorcia V, Valladares M, Holló G. Treatment of open angle glaucoma or ocular hypertension with preservative-free tafluprost/timolol fixed dose combination in a real-world setting: analysis by diagnostic sub-group at study entry. EVER 2021 online congress.
11. Oddone F, Fassari C, Iester M, Holló G, Lopez-Lopez F: Treatment of open angle glaucoma or ocular hypertension with preservative-free tafluprost/timolol fixed dose combination in a real-world clinical practice setting: a cross country subanalysis. EVER 2021 online congress.
12. Sándor NG, Géczy A, Kóthy P, Holló G. Szorongás, depresszió és életminőség vizsgálata fájdalommentes egyik szemükre látásukat elvesztett glaukóma betegek körében. Magyar Psychologiai Táraság XXIX. kongresszusa 2021, Székesfehérvár 26-28 August 2021.
13. Holló G. Modern automated perimetry for glaucoma. Glaucoma +2021, International Congress of the Glaucoma Society of Ukraine, Kiev, 3 September 2021.
14. Holló G. Preservative-free multidose dorzolamide/timolol fixed combination for glaucoma and ocular surface health. Glaucoma +2021, International Congress of the Glaucoma Society of Ukraine, Kiev, 3 September 2021.
2022. év
15. Holló G: OCT angiography for glaucpma detection and detection of glaucomatous progression. Glaucoma University, international congress, St. Petersburg 24-25. February 2022.
16. Holló G. OCT angiography for glaucoma: detection and progression analysis. 5th Serbian Glaucoma Congress with Internatioanl Participation, Kopaonik, 14-15 May 2022.
17. Holló G, Kirwan J, Lopez-Lopez F, Zimina M, Fassari C, Oddone F. Responder rate and investigator/patient-reported assessment of efficacy and tolerability regarding the preservative-free tafluprost/timolol fixed-dose combination in the treatment of open-angle glaucoma and ocular hypertension: country-level analysis from the VISIONARY study. 15th Congress of the European Glaucoma Society, Athens 4-8 June, 2002.
18. Stalmans I, Holló G, Hommer A, Belda J-I, Oddone F on behalf of
the MERCURY 3 Study Group. Efficacy and tolerability of netarsudil 0.02%/latanoprost 0.005% compared with bimatoprost 0.03%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension: findings from the MERCURY 3 study. 15th Congress of the European Glaucoma Society, Athens 4-8 June, 2002.
19. Holló G, Kirwan J, Lopez-Lopez F, Zimina M, Fassari C, Oddone F. Baseline intraocular pressure affects treatment outcome with the preservative-free tafluprost/timolol fixed-dose combination in open angle glaucoma and ocular hypertension: subanalysis from the VISIONARY study. 15th Congress of the European Glaucoma Society, Athens 4-8 June, 2002.
20. Holló G. How to put glaucoma patients in the center of glaucoma management? 15th Congress of the European Glaucoma Society, Athens 4-8 June, 2002.
21. Holló G. A nemzetközi VISIONARY vizsgálat eredményei II. A megelőző monoterápia hatása a konzerválószer-mentes tafluprost/timolol fix kombinációra váltás eredményére. Magyar Szemorvostársaság kongresszusa, Bükfürdő 2020. június 16-18.
22. Stalmans I, Holló G, Hommer A, Belda JI, Oddone F, Lim KS, on behalf of the MERCURY 3 Study Group. Efficacy and tolerability of netarsudil 0.02%/latanoprost 0.005% versus bimatoprost 0.03%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension: findings from the MERCURY 3 studyThe UKEGS Congress 2022, Birmingham 19-20 October 2022.
23. Holló G. From the EGS guidelines to real world practice. ESASO (European School for Advanced Studies in Ophthalmology) Parma, 17 September 2022.
24. Holló G. Sharing experience among experts: clinical cases’ discussion. ESASO (European School for Advanced Studies in Ophthalmology) Parma, 17 September 2022.
25. Holló G. Octopus perimetry - theoretical and practical, 2-h course. Congress of the Romanian Society of Glaucoma, 17. November 2022, Brassó
26. Holló G. Pathophysiology of pseudoexfoliative syndrome and pseudoexfoliative glaucoma. Congress of the Romanian Society of Glaucoma, 17. November 2022, Brassó
2023. év
27. Holló G. OCT angiography for glaucoma in 2023. Review lecture. 8th International Symposium "Glaucoma Cosódes" 11 March 2023, Zagreb.
28. Holló G. A cataracta műtét hatása a glaucomás beteg ellátására. Összefoglaló előadás. In: Holló G. Cataracta műtét egyéb szembetegségekben, szimpózium. SHIOL 2023-Magyar Műlencse Implantációs és Refraktív Sebészeti Társaság kongreszusa, Siófok, 23-25. Marcius 2023.
29. Holló G. Netarsudil/latanoprost versus bimatoprost/timolol fix szemcsepp kezelés nyitott zugú glaucomában és ocularis hypertensioban: a MERCURY 3 vizsgálat.Magyar Szemorvostársaság Kongresszusa, 22 June 2023, Bükkfürdő.
30. Holló G. The effect of prior medication use on IOP-lowering efficacy of netarsudil 0.02%/latanoprost 0.005% in patients with glaucoma: an exploratory analysis from MERCURY-3. SOE 2023 Prague, 16 June 2023.
31. Fichtl M, Oddone F, Holló G, Voykov B, Stalmans I. Examining the characteristics of conjunctival hyperaemia: associated with ROCK inhibition and prostaglandin treatment. SOE 2023 Prague, 16 June 2023.
32. Holló G. Advances in OCT angiography for glaucoma. World Glaucoma Congress 2023, Rome 28 June-01 July 2023.
33. Holló G. At the interest of positive patient outcomes. Can we Provide consistent IOP control without compromising patients' quality of life? Symposium lecture. World Glaucoma Congress 2023, Rome 28 June-01 July 2023.
34. Holló G. Pseudoexfoliative glauccoma. World Glaucoma Congress 2023, Rome 28 June-01 July 2023.
35. Holló G, Schweitzer C, Stalmans I. IOP-lowering efficacy of netarsudil/latanoprost in patients with glaucoma stratified by prior medication use: an exploratory analysis from MERCURY-3. Wold Glaucoma Congress 2023, Rome 28 June-01 July 2023.
36. Oddone F, Fichtl M, Holló G, Voykov B, Stalmans I. Examining the characteristics of conjunctival hyperaemia: associated with ROCK inhibition and prostaglandin treatment. Wold Glaucoma Congress 2023, Rome 28 June-01 July 2023.
37. Holló G. Treatment Paradigm and Sequencing of Anti-glaucoma Medications. In: Glaucoma Expert Talks, accredited by Royal College of Ophthalmologist, UK, 08 July 2023, India Centers - online lectures
Fő tevékenység a Prima Medica Egészségközpontban:
Professzor Dr. Holló Gáborral , a Szemészeti Központ vezetőjével, glaukóma specialistájával számos alkalommal beszélgettünk a szem fénytörési hibáiról, valamint a szem fénytörési hibáit okozó szemészeti elváltozások gyakorlati és klinikai következményeiről. A ...
A zöldhályogról (glaukómáról) már számos alkalommal beszélgettünk Prof. Dr. Holló Gáborral , a Szemészeti Központ vezetőjével, glaukóma specialistájával. A jelen alkalommal egy kifejezetten érdekességnek számító kérdéskörrel foglalkozunk a zöldhályog ...
Prof. Dr. Holló Gáborral , a Szemészeti Központ vezetőjével, glaukóma specialistával folytatott korábbi beszélgetéseink során számos alkalommal ejtettünk szót különböző szemészeti betegségekről, ezek tüneteiről, okairól és kezeléséről. A jelen alkalommal egy, a betegek által ...